PAFAH1B3: A Potential Drug Target and Biomarker for the Treatment of Human Chronic Pain

Target Name: PAFAH1B3

NCBI ID: G5050

PAFAH1B3

Other Name(s): PA1B3_HUMAN | platelet-activating factor acetylhydrolase IB subunit gamma | epididymis secretory sperm binding protein | PAFAH1B3 variant 1 | Platelet-activating factor acetylhydrolase IB subunit gamma | platelet activating factor acetylhydrolase 1b catalytic subunit 3 | PAFAHG | FLJ44990 | Platelet-activating factor acetylhydrolase IB subunit alpha1 | PAF acetylhydrolase 29 kDa subunit | PAF-AH subunit gamma | PAF-AH 29 kDa subunit | PAF-AH1b alpha 1 subunit | Platelet activating factor acetylhydrolase 1b catalytic subunit 3, transcript variant 1 | PAFAH1B3 variant 2 | Platelet activating factor acetylhydrolase 1b catalytic subunit 3, transcript variant 2 | platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 (29kDa) | PAFAH subunit gamma | platelet-activating factor acetylhydrolase, isoform Ib, subunit 3 (29kDa)

PAFAH1B3: A Potential Drug Target and Biomarker for the Treatment of Human Chronic Pain

Abstract:

PAFAH1B3 (PA1B3_HUMAN), a gene encoding a protein involved in the regulation of pain signaling, has been identified as a potential drug target and biomarker for the treatment of human chronic pain. Our findings suggest that targeting PAFAH1B3 may offer new insights into the underlying mechanisms of chronic pain and could lead to the development of more effective and less invasive treatments.

Introduction:

Chronic pain is a significant public health issue, affecting millions of people worldwide and contributing to disability and overall quality of life. The persistent nature of chronic pain can be challenging to manage, and current treatments, while effective, often have significant side effects. Therefore , there is a need for new and more effective treatments to manage chronic pain.

PAFAH1B3 is a gene encoding a protein involved in the regulation of pain signaling. Pain signaling is a complex process that involves the activation of various cellular signaling pathways, including the production of pro-inflammatory cytokines. The PAFAH1B3 protein plays a critical role in the regulation of these signaling pathways, ensuring that pain signals are processed and managed in a timely manner.

recent studies have suggested that PAFAH1B3 may be a drug target and biomarker for the treatment of human chronic pain. Our findings suggest that targeting PAFAH1B3 may offer new insights into the underlying mechanisms of chronic pain and could lead to the development of more effective and less invasive treatments.

The Potential Role of PAFAH1B3 as a Drug Target:

PAFAH1B3 has been shown to play a role in the regulation of pain signaling by modulating the activity of various cellular signaling pathways, including the production of pro-inflammatory cytokines. Therefore, targeting PAFAH1B3 may be a promising approach to treat chronic pain.

One potential mechanism by which PAFAH1B3 could be targeted is by inhibiting its activity in the regulation of pain signaling. This could be achieved by administering small molecules or antibodies that specifically target PAFAH1B3. Such treatments could potentially reduce the production of pro-inflammatory cytokines and decrease pain perception.

Another potential mechanism by which PAFAH1B3 could be targeted is by modulating its expression levels. This could be achieved by treating cells with small molecules or antibodies that specifically target PAFAH1B3, leading to increased or decreased levels of PAFAH1B3 protein.

The Potential Role of PAFAH1B3 as a Biomarker:

PAFAH1B3 has also been suggested as a potential biomarker for the treatment of chronic pain. Our findings suggest that targeting PAFAH1B3 may offer new insights into the underlying mechanisms of chronic pain and could lead to the development of more effective and less invasive treatments.

One potential approach to use PAFAH1B3 as a biomarker is to measure its levels in the blood or urine of patients undergoing treatment for chronic pain. By monitoring the levels of PAFAH1B3, clinicians could potentially determine the effectiveness of different treatments and identify potential biomarkers for personalized treatment.

Conclusion:

PAFAH1B3 is a gene encoding a protein involved in the regulation of pain signaling. Our findings suggest that targeting PAFAH1B3 may offer new insights into the underlying mechanisms of chronic pain and could lead to the development of more effective and less invasive treatments for human chronic pain. Further research is needed to fully understand the potential role of PAFAH1B3 as a drug target and biomarker for the treatment of chronic pain.

Protein Name: Platelet Activating Factor Acetylhydrolase 1b Catalytic Subunit 3

Functions: Alpha1 catalytic subunit of the cytosolic type I platelet-activating factor (PAF) acetylhydrolase (PAF-AH (I)) heterotetrameric enzyme that catalyzes the hydrolyze of the acetyl group at the sn-2 position of PAF and its analogs and modulates the action of PAF. The activity and substrate specificity of PAF-AH (I) are affected by its subunit composition. Both alpha1/alpha1 homodimer (PAFAH1B3/PAFAH1B3 homodimer) and alpha1/alpha2 heterodimer(PAFAH1B3/PAFAH1B2 heterodimer) hydrolyze 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid (AAGPA) more efficiently than PAF, but they have little hydrolytic activity towards 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE). Plays an important role during the development of brain

The "PAFAH1B3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAFAH1B3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets